REGENXBIO Inc. (NASDAQ:RGNX) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $23.18.

A number of equities analysts recently commented on RGNX shares. Zacks Research upgraded REGENXBIO from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Morgan Stanley reiterated an “overweight” rating and set a $18.00 price target on shares of REGENXBIO in a research note on Friday, August 7th. UBS Group reiterated a “positive” rating on shares of REGENXBIO in a research note on Friday, November 6th. HC Wainwright reissued a “buy” rating on shares of REGENXBIO in a research report on Monday, September 28th. Finally, Mizuho set a $18.00 price objective on shares of REGENXBIO in a research note on Friday, November 6th.

View Our Latest Analysis on REGENXBIO

Institutional Investors Weigh In On REGENXBIO

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of REGENXBIO during the 2nd quarter worth about $76,641,000. Bank of America Corp DE acquired a new position in REGENXBIO in the second quarter valued at approximately $6,212,000. Integral Health Asset Management LLC boosted its holdings in REGENXBIO by 50.0% in the third quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the biotechnology company’s stock valued at $9,036,000 after purchasing an additional 400,000 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in REGENXBIO by 18.3% in the third quarter. Goldman Sachs Group Inc. now owns 1,681,187 shares of the biotechnology company’s stock valued at $12,659,000 after purchasing an additional 259,734 shares during the last quarter. Finally, Corient Private Wealth LP acquired a new stake in REGENXBIO during the second quarter worth approximately $2,608,000. 88.08% of the stock is currently owned by institutional investors and hedge funds.

REGENXBIO Stock Down 4.2%

RGNX opened at $7.32 on Thursday. REGENXBIO has a 52 week low of $5.45 and a 52 week high of $16.19. The business has a fifty day simple moving average of $7.62 and a 200-day simple moving average of $8.88. The firm has a market cap of $484.00 million, a P/E ratio of -2.28 and a beta of 1.24.

REGENXBIO (NASDAQ:RGNX – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.67. The firm had revenue of $9.16 million for the quarter, compared to the consensus estimate of $10.89 million. REGENXBIO had a negative return on equity of 203.98% and a negative net margin of 113.85%. Sell-side analysts expect that REGENXBIO will post -3.01 earnings per share for the current year.

About REGENXBIO

(Get Free Report)

REGENXBIO Inc. is a biotechnology company focused on developing gene therapies for inherited diseases and other serious conditions. Founded in 2008 and headquartered in Rockville, Maryland, the company uses its proprietary NAV AAV gene-delivery platform to develop treatments intended to deliver genetic material to patients’ cells. Its research programs have included RGX-314, an investigational gene therapy for retinal diseases such as wet age-related macular degeneration, and candidates for conditions including Hunter syndrome and Duchenne muscular dystrophy.

Featured Stories

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.